1. Home
  2. BGLC vs IMNN Comparison

BGLC vs IMNN Comparison

Compare BGLC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$2.28

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

N/A

Current Price

$3.17

Market Cap

11.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGLC
IMNN
Founded
2017
1982
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
11.0M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
BGLC
IMNN
Price
$2.28
$3.17
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
8.7K
22.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
45.78
25.00
EPS
N/A
N/A
Revenue
$9,510,646.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.37
52 Week High
$15.19
$9.32

Technical Indicators

Market Signals
Indicator
BGLC
IMNN
Relative Strength Index (RSI) 36.35 45.08
Support Level $1.92 $3.03
Resistance Level $2.73 $4.26
Average True Range (ATR) 0.15 0.22
MACD 0.05 0.02
Stochastic Oscillator 13.11 27.36

Price Performance

Historical Comparison
BGLC
IMNN

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: